New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:43 EDTLMNXLuminex upside potential underappreciated, says Leerink
Leerink says its due diligence indicates the upside potential of Luminex shares is being underappreciated at current levels. The firm thinks the company's Technology unit is a growth business and it keeps an Outperform rating on the name with a $23 price target.
News For LMNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
06:40 EDTLMNXLuminex to host conference call
Subscribe for More Information
06:31 EDTLMNXLuminex receives FDA clearance for ARIES System, ARIES HSV 1&2 Assay
Luminex announced that it has received FDA clearance for the company's ARIES System and ARIES HSV 1&2 Assay. ARIES is a sample to answer system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. ARIES uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and Batch testing IVD and MultiCode Analyte Specific Reagents can be run simultaneously with a common Universal Assay Protocol. An integrated touchscreen PC eliminates the need for a separate computer, stand-alone keyboard, and mouse; thus maximizing valuable bench space. The company anticipates market launch in the next few weeks and a formal introduction at the Association for Molecular Pathology annual meeting in Austin, Texas, November 4-7, 2015.
September 25, 2015
12:53 EDTLMNXLuminex management to meet with William Blair
Meeting to be held in Chicago on September 30 hosted by William Blair.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use